ZURA

Zura Bio Limited

Fundamental data last updated:November 14, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

03/18/2027

Business Summary

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

 


Analyze ZURA on TradingView

VALUATION

P/E

-0.88

Market Cap ($M USD)

$95.35M

Forward P/E

-5.43

PEG

-0.26

PRICE TO SALES

0.00

PRICE TO BOOK

0.71

EV / EBITDA

0.97

5-Year Average P/E

Free Cash Flow Yield

-85.67%

DCF Value

$1.15

Graham Number

N/A

Price to FCF

-1.17

EV to FCF

1.13

Earnings Yield

-73.98%

FCF Yield

-85.67%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.73

Next Year EPS Growth Estimate

-$0.82

Next Year Revenue Growth Estimate

$8.33M

Return on Equity (ROE)

-53.97%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00

Piotroski F-Score

2

Altman Z-Score

11.23

Return on Invested Capital (ROIC)

-56.63%

Current Ratio

11.29

Quick Ratio

11.29

Net Debt to EBITDA

1.98

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-0.64

REVENUE PER SHARE

$0.00

Analyze ZURA on TradingView

Gainseekers Quantitative Analysis

Summary

Zura Bio Limited’s valuation paints a complex picture. Recent pricing indicated it traded significantly below its DCF value, suggesting potential undervaluation. However, the negative Forward P/E and Earnings Yield highlight ongoing profitability challenges. The Altman Z-score of 11.06 suggests financial stability, but the market seems skeptical about growth prospects. The stock’s financial health is a mixed bag, with safety metrics clashing against poor earnings performance.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Zura Bio is well-positioned to leverage AI for drug discovery and personalized medicine. The industry's inherent adaptability to tech advancements could provide resilience against disruptive shifts. However, execution will be key in translating these opportunities into tangible results.

The Bull Case

For the value-driven investor, Zura Bio offers intriguing prospects. Despite a negative ROIC, the company's debt-free balance sheet and high current ratio of 11.29 indicate strong liquidity. The Piotroski F-Score of 2 is low, but the Altman Z-score suggests a robust financial footing. These factors, combined with a consensus "Buy" rating, hint at potential upside if management can capitalize on growth opportunities.

The Bear Case

Zura Bio's structural weaknesses are glaring. The negative EPS and FCF Yield underscore severe profitability issues. Trading at a Price/Book of 2.90 without meaningful sales or profit margins raises red flags about valuation. The stock's distance from its 52-week high suggests limited technical momentum, further complicating the investment thesis.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$20.00

Institutional Ownership %

1-Year Beta

-0.04

Insider Buying % (6 Mo)

Distance to 52-Week High

651.59%

Distance to 52-Week Low

5.44%

EARNINGS SURPRISE %

1.93%

50-DAY SMA

$4.45

200-DAY SMA

$5.20

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.